CL2010000521A1 - Isolated antibody or fragment that blocks the binding of the protein binding wise; cdr sequences of the light and heavy chain; immunogenic polypeptide of wise; pharmaceutical composition comprising said antibody. - Google Patents

Isolated antibody or fragment that blocks the binding of the protein binding wise; cdr sequences of the light and heavy chain; immunogenic polypeptide of wise; pharmaceutical composition comprising said antibody.

Info

Publication number
CL2010000521A1
CL2010000521A1 CL2010000521A CL2010000521A CL2010000521A1 CL 2010000521 A1 CL2010000521 A1 CL 2010000521A1 CL 2010000521 A CL2010000521 A CL 2010000521A CL 2010000521 A CL2010000521 A CL 2010000521A CL 2010000521 A1 CL2010000521 A1 CL 2010000521A1
Authority
CL
Chile
Prior art keywords
wise
binding
antibody
fragment
blocks
Prior art date
Application number
CL2010000521A
Other languages
Spanish (es)
Inventor
Mei-Mei Tsai
Xueming Qian
Kevin Graham
Grant Shimamoto
Barbara S Tipton
Aaron George Winters
Li Zhang
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Priority to CL2010000521A priority Critical patent/CL2010000521A1/en
Publication of CL2010000521A1 publication Critical patent/CL2010000521A1/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Anticuerpo aislado o fragmento que bloquea la fijación de la unión de la proteína wise; secuencias de cdr de la cadena liviana y pesada; polipéptido inmunogénico de wise; composición farmacéutica que comprende dicho anticuerpo.Isolated antibody or fragment that blocks the binding of the wise protein binding; cdr sequences of the light and heavy chain; immunogenic polypeptide of wise; pharmaceutical composition comprising said antibody.

CL2010000521A 2010-05-20 2010-05-20 Isolated antibody or fragment that blocks the binding of the protein binding wise; cdr sequences of the light and heavy chain; immunogenic polypeptide of wise; pharmaceutical composition comprising said antibody. CL2010000521A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CL2010000521A CL2010000521A1 (en) 2010-05-20 2010-05-20 Isolated antibody or fragment that blocks the binding of the protein binding wise; cdr sequences of the light and heavy chain; immunogenic polypeptide of wise; pharmaceutical composition comprising said antibody.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2010000521A CL2010000521A1 (en) 2010-05-20 2010-05-20 Isolated antibody or fragment that blocks the binding of the protein binding wise; cdr sequences of the light and heavy chain; immunogenic polypeptide of wise; pharmaceutical composition comprising said antibody.

Publications (1)

Publication Number Publication Date
CL2010000521A1 true CL2010000521A1 (en) 2011-03-11

Family

ID=66221011

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2010000521A CL2010000521A1 (en) 2010-05-20 2010-05-20 Isolated antibody or fragment that blocks the binding of the protein binding wise; cdr sequences of the light and heavy chain; immunogenic polypeptide of wise; pharmaceutical composition comprising said antibody.

Country Status (1)

Country Link
CL (1) CL2010000521A1 (en)

Similar Documents

Publication Publication Date Title
UA112416C2 (en) FAP ANTIBODY AND METHODS OF ITS APPLICATION
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
EA201171494A1 (en) MIMETIC PROTEINS SMAC
MX2018007630A (en) Antibodies to matrix metalloproteinase 9.
CR20120210A (en) LINK PROTEINS TO THE ANTIGEN IL-23 HUMANS
CR20120371A (en) PCSK9 ANTAGONISTS
CY1115091T1 (en) SPECIFIC PROTECTION ANTIGEN PROTECTION PROTEINS
EA201791693A1 (en) HETERODIMERNY IMMUNOHLOBULINS
EA201790664A1 (en) ANTIBODIES AGAINST MEZOTELINE AND IMMUNOCONJUGATES
EA201170242A1 (en) MODIFIED BULL POLYPEPTIDES G-CSF AND THEIR APPLICATION
EA201390929A1 (en) ANTIBODIES TO PCSK9 AND METHODS OF THEIR APPLICATION
ECSP12012272A (en) PROTEINS THAT JOIN TNF-?
EA200802170A1 (en) LYOPHILIZED COMPOSITION OF THERAPEUTIC PEPTIDE ANTIBODY
AR083747A1 (en) ANTI-IL-23 ANTIBODIES
EA201390254A1 (en) MODIFIED RELAXIN POLYPEPTIDES AND THEIR APPLICATION
EA201100300A1 (en) COMPOSITIONS AND METHODS INTENDED FOR THE DIRECTED IMPACT OF ANTIBODIES ON C5 COMPLEMENT SYSTEM
PH12014501931A1 (en) Antibodies to matrix metalloproteinase 9
ES2684475T3 (en) Proteins that bind to beta amyloid
MX346500B (en) Methods and compositions for neural disease immunotherapy.
ES2639026T3 (en) Totally human antibodies specific for CADM1
CL2012003094A1 (en) Isolated bivalent antibody or bivalent fragment thereof, which acts on lrp6 enhancing a wnt signal by grouping one or more lrp6 receptors in the presence of a lrp6 binding protein; nucleic acid encoding it; vector comprising said nucleic acid; pharmaceutical composition comprising a multivalent anti-lrp6 antibody; and its use to treat cancer.
EP2566890A4 (en) Anti-pai-1 antibodies and methods of use thereof
EA201291065A1 (en) ANTIBODIES AGAINST VLA-4
EP3087185A4 (en) Antibodies comprising c-terminal light chain polypeptide extensions and conjugates and methods of use thereof
WO2014144542A3 (en) Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same